2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells $25,350,607.23 in Stock

2seventy bio, Inc. (NASDAQ:TSVT) major shareholder Global Healthcare Master Kynam sold 5,142,111 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $4.93, for a total value of $25,350,607.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

2seventy bio Stock Performance

Shares of TSVT opened at $4.95 on Friday. The company has a market capitalization of $255.36 million, a P/E ratio of -2.66 and a beta of 1.73. 2seventy bio, Inc. has a one year low of $2.29 and a one year high of $5.99. The stock has a 50-day moving average price of $2.76 and a 200 day moving average price of $3.69.

Institutional Trading of 2seventy bio

Several institutional investors and hedge funds have recently bought and sold shares of TSVT. GSA Capital Partners LLP acquired a new stake in 2seventy bio during the third quarter valued at approximately $64,000. Intech Investment Management LLC acquired a new stake in 2seventy bio during the third quarter valued at approximately $69,000. FMR LLC raised its stake in 2seventy bio by 22.0% during the third quarter. FMR LLC now owns 148,545 shares of the company’s stock valued at $701,000 after buying an additional 26,738 shares in the last quarter. BBR Partners LLC raised its stake in 2seventy bio by 620.0% during the third quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock valued at $850,000 after buying an additional 155,000 shares in the last quarter. Finally, PDT Partners LLC acquired a new stake in 2seventy bio during the third quarter valued at approximately $244,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on TSVT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 2seventy bio in a research report on Friday, March 7th. Leerink Partners reissued a “market perform” rating and issued a $5.00 price target (down previously from $9.00) on shares of 2seventy bio in a report on Tuesday, March 11th. Morgan Stanley reduced their price target on 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating for the company in a report on Friday. Finally, Leerink Partnrs downgraded 2seventy bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, 2seventy bio presently has a consensus rating of “Hold” and an average price target of $6.67.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.